The combination of IL-21 and IFN-α boosts STAT3 activation, cytotoxicity and experimental tumor therapy

Molecular Immunology

Volumn 46, Issue 5, 2009, Pages 812-820

  Eriksen, Karsten W ^a   Søndergaard, Henrik ^b   Woetmann, Anders ^c   Krejsgaard, Thorbjørn ^c   Skak, Kresten ^b   Geisler, Carsten ^a   Wasik, Mariusz A ^d   Ødum, Niels ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cytokines; Cytotoxicity; Human; Signal transduction; Tumor therapy

Indexed keywords

INTERLEUKIN 21; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 21; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; SIGNAL TRANSDUCTION; TARGET CELL;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; JURKAT CELLS; K562 CELLS; KILLER CELLS, NATURAL; MICE; NEOPLASMS; STAT3 TRANSCRIPTION FACTOR;

EID: 59449094425     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.09.006     Document Type: Article

References (37)

1. Alexander W.S., and Hilton D.J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu. Rev. Immunol. 22 (2004) 503-529
2. Brandt K., Singh P.B., Bulfone-Paus S., and Ruckert R. Interleukin-21: a new modulator of immunity, infection, and cancer. Cytokine Growth Factor Rev. 18 (2007) 223-232
3. Brassard D.L., Grace M.J., and Bordens R.W. Interferon-alpha as an immunotherapeutic protein. J. Leukoc. Biol. 71 (2002) 565-581
4. Brender C., Nielsen M., Ropke C., Nissen M.H., Svejgaard A., Billestrup N., Geisler C., and Odum N. Interferon-alpha induces transient suppressors of cytokine signalling expression in human T cells. Exp. Clin. Immunogenet. 18 (2001) 80-85
5. Caldenhoven E., van Dijk T.B., Solari R., Armstrong J., Raaijmakers J.A.M., Lammers J.W.J., Koenderman L., and De Groot R.P. STAT3beta, a splice variant of transcription factor STAT3, is a dominant negative regulator of transcription. J. Biol. Chem. 271 (1996) 13221-13227
6. Caraglia M., Marra M., Pelaia G., Maselli R., Caputi M., Marsico S.A., and Abbruzzese A. Alpha-interferon and its effects on signal transduction pathways. J. Cell Physiol. 202 (2005) 323-335
7. Davis I.D., Skrumsager B.K., Cebon J., Nicholaou T., Barlow J.W., Moller N.P., Skak K., Lundsgaard D., Frederiksen K.S., Thygesen P., and McArthur G.A. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin. Cancer Res. 13 (2007) 3630-3636
8. Dickensheets H.L., Venkataraman C., Schindler U., and Donnelly R.P. Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 10800-10805
9. Eriksen K.W., Kaltoft K., Mikkelsen G., Nielsen M., Zhang Q., Geisler C., Nissen M.H., Röpke C., Wasik M.A., and Ødum N. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia 15 (2001) 787-793
10. Eriksen K.W., Lovato P., Skov L., Krejsgaard T., Kaltoft K., Geisler C., and Odum N. Increased sensitivity to interferon-alpha in psoriatic T cells. J. Invest. Dermatol. 125 (2005) 936-944
11. Eriksen K.W., Sommer V.H., Woetmann A., Rasmussen A.B., Brender C., Svejgaard A., Skov S., Geisler C., and Odum N. Bi-phasic effect of interferon (IFN)-alpha: IFN-alpha up- and down-regulates interleukin-4 signaling in human T cells. J. Biol. Chem. 279 (2004) 169-176
12. Frederiksen K.S., Lundsgaard D., Freeman J.A., Hughes S.D., Holm T.L., Skrumsager B.K., Petri A., Hansen L.T., McArthur G.A., Davis I.D., and Skak K. IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol. Immunother. (2008)
13. Geisler C., Scholler J., Wahi M.A., Rubin B., and Weiss A. Association of the human CD3-zeta chain with the alpha beta-T cell receptor/CD3 complex. Clues from a T cell variant with a mutated T cell receptor-alpha chain. J. Immunol. 145 (1990) 1761-1767
14. Gimeno R., Lee C.K., Schindler C., and Levy D.E. Stat1 and Stat2 but not Stat3 arbitrate contradictory growth signals elicited by alpha/beta interferon in T lymphocytes. Mol. Cell Biol. 25 (2005) 5456-5465
15. Kaltoft K., Bisballe S., Rasmussen H.F., Thestrup-Pedersen K., Thomsen K., and Sterry W. A continuous T-cell line from a patient with Sezary syndrome. Arch. Dermatol. Res. 279 (1987) 293-298
16. Kaltoft K., Hansen B.H., Pedersen C.B., Pedersen S., and Thestrup-Pedersen K. Common clonal chromosome aberrations in cytokine-dependent continuous human T-lymphocyte cell lines. Cancer Genet. Cytogenet. 85 (1995) 68-71
17. Kaltoft K., Hansen B.H., and Thestrup-Pedersen K. Cytogenetic findings in cell lines from cutaneous T-cell lymphoma. Dermatol. Clin. 12 (1994) 295-304
18. Kotenko S.V., and Pestka S. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene 19 (2000) 2557-2565
19. Li Y., Chu N., Rostami A., and Zhang G.X. Dendritic cells transduced with SOCS-3 exhibit a tolerogenic/DC2 phenotype that directs type 2 Th cell differentiation in vitro and in vivo. J. Immunol. 177 (2006) 1679-1688
20. Mitani Y., Takaoka A., Kim S.H., Kato Y., Yokochi T., Tanaka N., and Taniguchi T. Cross talk of the interferon-alpha/beta signalling complex with gp130 for effective interleukin-6 signalling. Genes Cells 6 (2001) 631-640
21. +T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J. Immunol. 173 (2004) 900-909
22. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., Johnston J., Madden K., Xu W., West J., Schrader S., Burkhead S., Heipel M., Brandt C., Kuijper J.L., Kramer J., Conklin D., Presnell S.R., Berry J., Shiota F., Bort S., Hambly K., Mudri S., Clegg C., Moore M., Grant F.J., Lofton-Day C., Gilbert T., Rayond F., Ching A., Yao L., Smith D., Webster P., Whitmore T., Maurer M., Kaushansky K., Holly R.D., and Foster D. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408 (2000) 57-63
23. Pene J., Rousset F., Briere F., Chretien I., Bonnefoy J.Y., Spits H., Yokota T., Arai N., Arai K., and Banchereau J. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 6880-6884
24. Pignatelli M., Waters J., Brown D., Lever A., Iwarson S., Schaff Z., Gerety R., and Thomas H.C. HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection. Hepatology 6 (1986) 349-353
25. Rhodes J., Ivanyi J., and Cozens P. Antigen presentation by human monocytes: effects of modifying major histocompatibility complex class II antigen expression and interleukin 1 production by using recombinant interferons and corticosteroids. Eur. J. Immunol. 16 (1986) 370-375
26. Rogge L., Barberis-Maino L., Biffi M., Passini N., Presky D.H., Gubler U., and Sinigaglia F. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J. Exp. Med. 185 (1997) 825-831
27. Skak K., Kragh M., Hausman D., Smyth M.J., and Sivakumar P.V. Interleukin 21: combination strategies for cancer therapy. Nat. Rev. Drug Discov. 7 (2008) 231-240
28. Sleijfer S., Bannink M., Van Gool A.R., Kruit W.H., and Stoter G. Side effects of interferon-alpha therapy. Pharm. World Sci. 27 (2005) 423-431
29. Song H., Wang R., Wang S., and Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 4700-4705
30. Spolski R., and Leonard W.J. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 26 (2008) 57-79
31. Strengell M., Julkunen I., and Matikainen S. IFN-alpha regulates IL-21 and IL-21R expression in human NK and T cells. J. Leukoc. Biol. 76 (2004) 416-422
32. Takaoka A., Mitani Y., Suemori H., Sato M., Yokochi T., Noguchi S., Tanaka N., and Taniguchi T. Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. Science 288 (2000) 2357-2360
33. Takaoka A., and Yanai H. Interferon signalling network in innate defence. Cell Microbiol. 8 (2006) 907-922
34. Thompson J.A., Curti B.D., Redman B.G., Bhatia S., Weber J.S., Agarwala S.S., Sievers E.L., Hughes S.D., DeVries T.A., and Hausman D.F. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J. Clin. Oncol. 26 (2008) 2034-2039
35. Wang G., Tschoi M., Spolski R., Lou Y., Ozaki K., Feng C., Kim G., Leonard W.J., and Hwu P. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 63 (2003) 9016-9022
36. Woetmann A., Lovato P., Eriksen K.W., Krejsgaard T., Labuda T., Zhang Q., Mathiesen A.M., Geisler C., Svejgaard A., Wasik M.A., and Odum N. Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood 109 (2007) 3325-3332
37. Yadav A., Kalita A., Dhillon S., and Banerjee K. JAK/STAT3 pathway is involved in survival of neurons in response to insulin-like growth factor and negatively regulated by suppressor of cytokine signaling-3. J. Biol. Chem. 280 (2005) 31830-31840